<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28957">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729753</url>
  </required_header>
  <id_info>
    <org_study_id>CP0014</org_study_id>
    <nct_id>NCT02729753</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate CryoBalloon™ Full Ablation System for Ablation of Human Esophageal Epithelium</brief_title>
  <official_title>Clinical Study to Evaluate the CryoBalloon™ Full Ablation System for Ablation of Human Esophageal Epithelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C2 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C2 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the CryoBalloon™ Full Ablation System for the ablation of human
      esophageal epithelium in patients scheduled to undergo esophagectomy for reasons unrelated
      to the objective of the study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcomes for the study are the safety and treatment effect of the CryoBalloon™
      Ablation System. An Esophagectomy will be performed as scheduled following the ablation
      procedure; histopathological analysis of surgically-resected specimens will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the CryoBalloon™ Ablation System by incidence of serious, device-related adverse events</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment effect of the CryoBalloon™ Ablation System will be evaluated by depth and uniformity of ablation effect in the esophagus.</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Performance: ease of deployment and procedure time both pre and post procedure</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>CryoBalloon™ Full Ablation System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>To evaluate CryoBalloon™ Full Ablation System for the ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CryoBalloon™ Full Ablation System</intervention_name>
    <description>Tissue Ablation using CryoBalloon™ Full Ablation System</description>
    <arm_group_label>CryoBalloon™ Full Ablation System</arm_group_label>
    <other_name>CryoBalloon Ablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum of one 3cm area of non-ulcerated columnar-lined esophagus or squamous-lined
             tissue suitable for ablation

          -  Older than 18 years of age

          -  Requires a clinically necessary esophagectomy for esophageal cancer or other
             indications.

        Exclusion Criteria:

          -  Patient has esophageal narrowing limiting access to the intended sites of ablation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Louie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center and Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcia Wachna, RN</last_name>
    <phone>650-316-8601</phone>
    <email>marcia@c2therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Oregon Clinic-The Foundation for Surgical Innovation and Education</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Sharata</last_name>
      <phone>503-281-0561</phone>
      <email>drsharata@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Christy Dunst, MD</last_name>
      <phone>503-281-0561</phone>
      <email>drsharata@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital (West Penn Hospital)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Lloyd</last_name>
      <phone>412-578-1343</phone>
      <email>elloyd1@wpahs.org</email>
    </contact>
    <contact_backup>
      <last_name>Blair Jobe, MD</last_name>
      <phone>412-578-1343</phone>
      <email>elloyd1@wpahs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhodette Francisco, R.N.</last_name>
      <phone>713-563-9155</phone>
      <email>rfrancisco@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Wayne Hofstetter, MD</last_name>
      <phone>713-563-9155</phone>
      <email>rfrancisco@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center and Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Smith, BS</last_name>
      <phone>206-386-2450</phone>
      <email>andrew.smith@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Brian Louie, MD</last_name>
      <phone>206-386-2450</phone>
      <email>andrew.smith@swedish.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>March 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
